{"data":{"type":"company_profile_ai","id":155980,"entity_id":"wefunder:company:155980","attributes":{"canonical_url":"https://wefunder.com/simplify.genomics","retrieval_urls":{"canonical":"https://wefunder.com/simplify.genomics","json":"https://wefunder.com/simplify.genomics.json","markdown":"https://wefunder.com/simplify.genomics.md","ai_json":"https://wefunder.com/simplify.genomics.ai.json","ai_text":"https://wefunder.com/simplify.genomics.ai.txt","changelog_json":"https://wefunder.com/simplify.genomics.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-07T05:03:09Z","generated_at":"2026-06-07T06:27:02Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":false,"privacy_mode":"unlisted","invite_only":false},"company":{"id":155980,"entity_id":"wefunder:company:155980","slug":"simplify.genomics","name":"Simplify Genomics","tagline":"The Tech-Enabled Platform Turning Genomic Data into Actionable Healthcare Solutions","location":"San Diego, CA","website":"https://simplifygenomics.com/","total_amount_raised":4999800,"total_investors":2819,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 4999800","citation":"https://wefunder.com/simplify.genomics#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-07T05:03:09Z","as_of":"2026-06-07T06:27:02Z","confidence":"high"},"observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-08T05:03:09Z"},{"claim_id":"claim-total-investors","text":"Total investors: 2819","citation":"https://wefunder.com/simplify.genomics#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-07T05:03:09Z","as_of":"2026-06-07T06:27:02Z","confidence":"high"},"observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-08T05:03:09Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 4999800","citation":"https://wefunder.com/simplify.genomics#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-07T05:03:09Z","as_of":"2026-06-07T06:27:02Z","confidence":"high"},"observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-08T05:03:09Z"},{"claim_id":"claim-total-investors","text":"Total investors: 2819","citation":"https://wefunder.com/simplify.genomics#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-07T05:03:09Z","as_of":"2026-06-07T06:27:02Z","confidence":"high"},"observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-08T05:03:09Z"}],"company_claims":{"tagline":"The Tech-Enabled Platform Turning Genomic Data into Actionable Healthcare Solutions","story":"More than 20 years after the first human genome was sequenced, genomics is stalled in a data flood. Human genomes are sequenced quickly and inexpensively, yet clinicians are left reviewing the first page of a highly limited report, leaving powerful data buried and unusable.Demand for whole genome sequencing is rising rapidly as sequencing costs decline. The challenge has shifted from a sequencing problem to a data problem as the industry struggles to make clinical sense of all the genomic information (6.4B pieces of data from one human genome!). Currently, the interpretation of the data is done by bioinformaticians and genomic scientists making subjective decisions on a tiny subset of data, and this reliance on people to make decisions is driving costs back up.As an industry, we are on the precipice of discovery that will enable the identification, creation, and commercialization of vastly improved patient treatments. By tapping into the full power of the genome, clinicians can quickly assess genomic similarities between patients, providing the right treatment to the right patient and limiting side effects. We believe this will revolutionize healthcare!We believe Simplify Genomics has created the next-generation platform to realize these discoveries and finally make use of the data flood.\u0026nbsp;Solving the Data Problem with Smart GenomeOver the last 7 years, Simplify Genomics has built Smart Genome, an automated genome reporting platform designed for scale to empower genomics in healthcare. Simply put, it makes practical clinical use of deep genomic data, finally bringing healthcare into the future.Since 2018, our platform has curated over 7,000 genes and millions of variants, producing over 10,000 clinically actionable whole genome reports. AI-driven and validated, our platform supports seamless content expansion, with nine versions released over seven years.Smart Genome was developed by an expert team under Craig Venter – the first person to sequence the human genome – and leveraged decades of insight to create our platform. Our Technology StackSimplify Genomics’ technology is a three-tiered suite to empower the future of genomics in healthcare.1. Simplify Genome: Clinical whole genome reporting CLIA-certified and CAP-accredited dry laboratory that delivers actionable insights from whole genome sequencing. Our content is AI-informed and explainable, ensuring scalable, fast, and reproducible clinical reporting.2. Simplify Search: Fast, accurate, insightful genome explorationAn AI technology platform that quickly provides access to raw genetic data, clinical information, and the latest insights in genomics. Similar to Google, users can access information through a user-friendly interface that queries hundreds of millions of genomic variants at the speed of thought.3. Simplify Data: Multi-source, rich data repository An aggregation of public, proprietary, and clinical data that empowers discovery and research, serving as the foundation of the Genome and Search platforms.For a more technical look at our Search platform, see the following video:With our groundbreaking solutions, we can finally interpret genomic data quickly enough and at the scale needed for clinical actionability. With the right data, we can match genetically similar patients to predictable outcomes, putting powerful science behind personalized healthcare. This technology moves us toward personalized medicine and can extend lifespans.Furthermore, our platform uses AI to quickly generate deeper reports, eliminating the need for costly manual work while significantly reducing time and expenses.Proven Company\u0026nbsp;Simplify Genomics started in 2016 under our former parent company, Human Longevity. Founded in 2013 by Craig Venter, the person credited with sequencing the first human genome, Human Longevity focused on developing solutions around the whole genome, with over $400 million in investment into the parent company.\u0026nbsp;In 2022, Simplify Genomics spun out of Human Longevity, leveraging years of expertise and $90 million of development to create our platform. Today, Human Longevity exclusively uses Simplify Genomics reports to guide clinical decisions for its Longevity Program.\u0026nbsp;Simplify has accomplished the following:\u0026nbsp;Built an automated AI system to produce clinical reports from raw genomic data seamlessly.Created a market-leading comprehensive genomic screening report that covers multiple diseases.Developed breakthrough search technology for instant analysis of genomic and clinical data.Assembled a database with over 35k whole genomes and 400 million unique variants – expected to surpass 100,000 whole genomes and more than 1 billion distinct variants in the next six months!Compiled a curated database of 1.6 million genetic variants, linking each to diseases and assessing their risk level.We have demonstrated initial market acceptance and revenue generation, generating between $1.5M and $2M of revenue annually, primarily from Human Longevity.(Forward-looking projections not guaranteed)Market Demanding ChangeAs sequencing prices rapidly decline after years of stagnation, the healthcare industry is moving to whole genome sequencing as a backbone, creating optimal timing for Simplify. Our initial target market is the large and growing concierge medicine and executive health market, which will use our reports as an addition to their current offerings. This market is eager for new content to differentiate itself and better treat its patients and our screening reports give them that edge. We are at the forefront of this transition.We believe this target market will allow Simplify to achieve positive cash flow in under 12 months and then expand into additional markets. Please note that future projections aren't guaranteed. Profitable Business ModelSimplify is a rare opportunity in the healthcare technology sector. Our profitability may be extremely close on the front end, and our valuation growth may be exponential on the back end. This is possible due to the $90M+ development funding prior to the spin-out and our team's deep experience.\u0026nbsp;\u0026nbsp;As Simplify’s solution is adopted, there are additional monetization streams, including significant recurring revenue opportunities through a subscription model.\u0026nbsp;(Forward-looking projections not guaranteed)Leading the CompetitionSimplify Genomics is entering a market poised for disruption. Current products have limited clinical utility. Our Smart Genome platform paves the way for something entirely new by equipping clinicians to fully leverage raw genomic data, positioning us to be a leader in an industry primed for major change.Our report is much broader, more clinically actionable, and lower in cost. Additionally, our search engine provides groundbreaking access to information that revolutionizes patient care by utilizing raw data beyond the clinical report at the speed of thought.Future OpportunitiesAs a lean company, we are hyper-focused on the short-term plan and commercializing our market-leading report. That being said, our full platform suite has significant future upside opportunities that can dramatically increase the business's enterprise value.Simplify can address multiple commercial avenues, such as an end-to-end reporting solution, large-scale Simplify Search adoption, and subscription models.There is ample industry precedent for acquisition in the healthcare technology sector - a likely outcome for Simplify Genomics in the foreseeable future.Precedent AcquisitionsPierian was acquired by VelseraEmedgene was acquired by IlluminaNof1 was acquired by QiagenDeepLens was acquired by ParadigmTrapelo Health was acquired by NeoGenomicsTeam of Industry ExpertsSimplify’s team consists of industry veterans with experience building and selling a health tech platform. Previously, working together at Human Longevity under industry pioneer Craig Venter, they developed the platform that is now Smart Genome, giving them deep expertise in its code and architecture.Our co-founder and CEO, Travis Lacey, has a background in business, including as an investment banker. Lacey built a successful oncology platform that sequenced high-quality data from tumor tissue and interpreted it into clinically relevant information for drug development. In 2020, it was acquired by NeoGenomics Laboratories, significantly exceeding investor expectations.We have successfully leveraged the strength of our lean but passionate team to get Simplify to its current state. The Use of FundsToday, Simplify Genomics is raising $5 million to expand commercially and continue the product development of Smart Genome.The investment thesis has been de-risked, given that Simplify has a clear market problem, a proven solution, a validated technology platform, CLIA certification and CAP accreditation, and initial market acceptance. In addition, we have $90M in prior development funding, and a clean cap table, making this opportunity a high-potential investment.\u0026nbsp;As genomics takes center stage in clinical, biotech and pharma markets, Simplify Genomics is strategically positioned to lead the future of personalized medicine. Join us in transforming genomic data to dramatically improve patient outcomes at the speed of thought!","quick_facts":["Tracking to $1.5M to $2M in ARR in 2024","Technology validated over 7+ years with 9 updated versions and 10k+ clinical reports issued","CEO previously built and sold a successful genomics tech platform","Spin out of genomic company founded by Craig Venter who sequenced the first human genome","De-risked investment with $90M prior development funding, clean cap table, and virtually no debt","Scalable, automated platform; able to profitably offer whole genome clinical report under $1,000","Our search engine rapidly analyzes data at 'speed of thought,' unlocking Google-like monetization"]},"computed_metrics":{"total_amount_raised":4999800,"total_investors":2819,"team_size":2,"featured_investor_count":2,"faq_count":5,"recent_post_count":4},"quick_facts":[{"claim_id":"claim-fact-1","value":"Tracking to $1.5M to $2M in ARR in 2024","citation":"https://wefunder.com/simplify.genomics#claim-fact-1","observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-14T05:03:09Z"},{"claim_id":"claim-fact-2","value":"Technology validated over 7+ years with 9 updated versions and 10k+ clinical reports issued","citation":"https://wefunder.com/simplify.genomics#claim-fact-2","observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-14T05:03:09Z"},{"claim_id":"claim-fact-3","value":"CEO previously built and sold a successful genomics tech platform","citation":"https://wefunder.com/simplify.genomics#claim-fact-3","observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-14T05:03:09Z"},{"claim_id":"claim-fact-4","value":"Spin out of genomic company founded by Craig Venter who sequenced the first human genome","citation":"https://wefunder.com/simplify.genomics#claim-fact-4","observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-14T05:03:09Z"},{"claim_id":"claim-fact-5","value":"De-risked investment with $90M prior development funding, clean cap table, and virtually no debt","citation":"https://wefunder.com/simplify.genomics#claim-fact-5","observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-14T05:03:09Z"},{"claim_id":"claim-fact-6","value":"Scalable, automated platform; able to profitably offer whole genome clinical report under $1,000","citation":"https://wefunder.com/simplify.genomics#claim-fact-6","observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-14T05:03:09Z"},{"claim_id":"claim-fact-7","value":"Our search engine rapidly analyzes data at 'speed of thought,' unlocking Google-like monetization","citation":"https://wefunder.com/simplify.genomics#claim-fact-7","observed_at":"2026-06-07T05:03:09Z","expires_at":"2026-06-14T05:03:09Z"}],"latest_fundraise":{"id":115326,"entity_id":"wefunder:fundraise:115326","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null},"investor_memos":[],"team":[{"id":4250744,"entity_id":"wefunder:company_role:4250744","name":"Travis Lacey","title":"Co-Founder and CEO","role":"founder","profile_url":"https://wefunder.com/travis.lacey"},{"id":4266121,"entity_id":"wefunder:company_role:4266121","name":"Wayne Delport","title":"Co-Founder and Chief Technology Officer","role":"founder","profile_url":"https://wefunder.com/wayne.delport"}],"featured_investors":[{"id":8752,"entity_id":"wefunder:company_investor_profile:8752","name":"Human Longevity Performance Impact Fund","profile_url":"https://wefunder.com/human.longevity.performance.impact.fund"},{"id":10239,"entity_id":"wefunder:company_investor_profile:10239","name":"Sukhjit Takhar","profile_url":"https://wefunder.com/sukhjit.takhar","endorsement_quote":"As an MD in concierge medicine in my own startup, I'm investing in Simplify because I see the transformative potential of genetic insights in enhancing personalized healthcare. In my practice, I'm dedicated to providing individualized care, and genomics represents a powerful tool to deepen this approach, allowing for more precise preventative and therapeutic strategies. Simplify aligns perfectly with my vision for proactive, relationship based medicine, as it brings advanced, accessible genetic information to patients in a way that can meaninfully impact their health outcomes. I'm also investing in Simplify because I trust Travis Lacey and his clear realistic vision for the company. Throughout multiple conversations, I've been impressed by his commitment to delivering true value without overselling, focusing on genuine advancements in genetic insights. This measured approach reassures me of the company's integrity and focus on long term impact."}],"relationships":[{"source_entity_id":"wefunder:company:155980","relation":"has_team_member","target_entity_id":"wefunder:user:4328529","target_url":"https://wefunder.com/travis.lacey"},{"source_entity_id":"wefunder:company:155980","relation":"has_team_member","target_entity_id":"wefunder:user:4335307","target_url":"https://wefunder.com/wayne.delport"},{"source_entity_id":"wefunder:company:155980","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:12221","target_url":"https://wefunder.com/human.longevity.performance.impact.fund"},{"source_entity_id":"wefunder:company:155980","relation":"has_featured_investor","target_entity_id":"wefunder:user:4544456","target_url":"https://wefunder.com/sukhjit.takhar"},{"source_entity_id":"wefunder:company:155980","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:184386","target_url":"https://wefunder.com/feed/184386"},{"source_entity_id":"wefunder:company:155980","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:184206","target_url":"https://wefunder.com/feed/184206"},{"source_entity_id":"wefunder:company:155980","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:179616","target_url":"https://wefunder.com/feed/179616"},{"source_entity_id":"wefunder:company:155980","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:177505","target_url":"https://wefunder.com/feed/177505"},{"source_entity_id":"wefunder:company:155980","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:115326"}],"faq":[{"question":"Hi, Very interesting. Can you please tell us about your IP portfolio? Thanks. Blessings","answer":"Thank you for your question. We have exclusive worldwide rights to the patents that we need for Simplify and the right to prosecute those patents. Please don't hesitate to let me know if you have more questions. Thank you for your consideration."},{"question":"Dear Sirs, I am Giovanni Diamante and I have tried to file an investment in Simplified Genomics, but I cannot close it to send it to you. What I am missing? Regards, Giovanni gfdiamante@yahoo.com","answer":"Giovanni - are you still having issues? I can talk to Wefunder about having someone follow-up with you. Thank you."},{"question":"Hello Travis, Greetings! Love your initiative. I am an Angel investor. Have few questions - Is there a liquidation preference or preference overhang in the cap table? - Given the uniqueness of the platform, wonder why Human Longevity is your only customer? Where do you see the...","answer":"No overhang or liquidation preference in the cap table - standard common and preferred. On the Human Longevity question, we are now bringing on new customers but it has all been through word of mouth. Part of use of funds will be to expand commercially - we are also launching in 1Q w a large imaging center combining our WG report with their WB MRI (cash pay). The revenue decline was all due to us continuing to bring our prices down to a point where we can drive more volume. At the same time, ..."},{"question":"I am an obstetrician/gynecologist and a functional medicine practitioner since 2005. I did my first microarray for methylation pathway with Dr Amy Yasko in 2005 and HLA gene typing in 2010 and have been practicing nutrigenomics since then with great relief of some symptoms, so...","answer":"Hi Bina, thanks for your interest and questions. We are excited about where we can take this company and our approach to scientifically-based preventative care. HLA-typing and methylation are areas of interest to us, but we must stay focused in the short term. I would like to address your specific questions. 1. For clinical genome interpretation, we rely on scientific findings from published studies, public and licensed genomic data sources, and our internal proprietary data. This allows us t..."},{"question":"I assume your company has patents regarding your technology. If so, I would add a section about that on Wefunder unless I missed it as I read through. If you do, roughly what does it cover/how do they set your company apart from any competitors?","answer":"Thank you for your question and suggestion. Yes we have been given exclusive worldwide license on the patents around our Search engine that allow users to search raw genomic and clinical information in a quick and efficient manner. The ability to upload thousands of whole genomes, get that information organized, and enable non-technical users to search that information in “google speed” is a huge differentiator from what is available on the market today. I would be happy to discuss further an..."}],"recent_posts":[{"id":184386,"entity_id":"wefunder:feed_item:184386","title":"Simplify Genomics / TMA Precision Health","preview":"In my most recent investor update, I touched on Simplify's mission, market landscape, and commercial progress this year. The message from the market is clear: we're seeing a major shift towards Whole Exome and Whole Genome sequencing.As one of our more active supporters, I wanted to personally invite you to a webinar I'm hosting on Wednesday, August 6th at 1pm with Josh Resnikoff, the CEO of TMA Precision Health, who has built a marketplace of solutions for self-funded employer health plans.I...","published_at":"2025-08-04T22:07:13Z","canonical_url":"https://wefunder.com/feed/184386"},{"id":184206,"entity_id":"wefunder:feed_item:184206","title":"Simplify Genomics | Investor Update – 1H 2025","preview":"Dear Investors,Thank you for your continued support of Simplify Genomics. We are energized by the progress made in the first half of 2025 and are optimistic about the growth trajectory ahead. In this update, we highlight key developments across the business, the broader market, and outline our priorities for the remainder of the year.Our MissionAt Simplify Genomics, we are revolutionizing clinical decision-making through genomic reporting and real-time genome exploration. Our platform is comp...","published_at":"2025-07-29T19:54:51Z","canonical_url":"https://wefunder.com/feed/184206"},{"id":179616,"entity_id":"wefunder:feed_item:179616","title":"Partnership Update","preview":"Simplify Genomics Investors,Your investment in Simplify Genomics helped us raise $5 million to revolutionize genomic diagnostics. Together, we’re transforming healthcare by making cutting-edge solutions more accessible to families. \u0026nbsp;In the spirit of periodic updates, I wanted to share a unique partner that we will be working with to broaden access to cutting-edge testing in the future.\u0026nbsp;O’Ryan Health is changing the paradigm of pediatric care and sharing our mission to use data as a ...","published_at":"2025-02-18T21:00:25Z","canonical_url":"https://wefunder.com/feed/179616"},{"id":177505,"entity_id":"wefunder:feed_item:177505","title":"My \"Why\" - The Story of My Father","preview":"Hello everyone. It’s Travis Lacey, CEO and co-founder of Simplify Genomics. Although I’ve been in the healthcare industry for almost 30 years, the grave importance of my work did not completely dawn on me until a recent battle my dad had with cancer. I wanted to take a moment to tell the story of why this Simplify Genomics’ platform is so powerful and important to me.Four years ago, my dad was diagnosed with late-stage cancer and the outlook was bleak. He was initially going to undergo standa...","published_at":"2024-11-15T02:24:38Z","canonical_url":"https://wefunder.com/feed/177505"}],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-07T06:27:02Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-07T05:03:09Z","as_of":"2026-06-07T06:27:02Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-07T05:03:09Z","as_of":"2026-06-07T06:27:02Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-07T06:27:02Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-07T06:27:02Z","confidence":"medium"}}}}}}